Literature DB >> 18339114

Markers for hepatitis A, B and C in methadone maintained patients: an unexpectedly high co-infection with silent hepatitis B.

Gavin Bart1, Paola Piccolo, Linqi Zhang, Ira Jacobson, Robert A Schaefer, Mary Jeanne Kreek.   

Abstract

AIMS: To determine the prevalence of hepatitis A, B and C viruses in patients attending a methadone maintenance clinic in New York City.
DESIGN: Cross-sectional.
SETTING: The Adult Services Clinic of Weill Cornell Medical College, an urban hospital-affiliated methadone program. PARTICIPANTS: Former heroin addicted adults (n = 103) on methadone maintenance therapy. MEASUREMENTS: Markers for hepatitis A virus [HAV immunoglobulin M (IgM) and imunoglobulin G (IgG)], hepatitis B [hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb) and hepatitis B core antibody (HBcAb)] and hepatitis C virus (HCVAb). Serum alanine aminotransferase (ALT) and quantitative HCV RNA were also obtained. Qualitative detection of HBV DNA and HCV genotype were obtained in a subset of subjects.
FINDINGS: More than 40% of subjects had markers for all three viruses. HCVAb was the most prevalent (83.5%), followed by HBcAb (65.0%), HAV IgG (46.1%) and HBsAb (41.1%). Hepatitis C RNA was detected in 70.6% of HCVAb positive subjects. While no subject had HBsAg, HBV DNA was detected in 26.4% of subjects who underwent this measure; all (n = 20) had HBcAb as their only HBV marker. The presence of HBV DNA did not influence ALT. Subjects with HCV RNA had higher ALTs than those without HCV RNA.
CONCLUSIONS: Most methadone-maintained subjects had at least one marker for viral hepatitis, with 41.8% having markers for HAV, HBV and HCV. A quarter of subjects had silent HBV infection, defined as the presence of HBV DNA in the absence of HBsAg. These subjects should be considered infectious and pose a public health risk.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339114      PMCID: PMC3810150          DOI: 10.1111/j.1360-0443.2008.02151.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  38 in total

Review 1.  Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

Authors:  C Bréchot; V Thiers; D Kremsdorf; B Nalpas; S Pol; P Paterlini-Bréchot
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

2.  Long-term methadone maintenance therapy: effects on liver function.

Authors:  M J Kreek; L Dodes; S Kane; J Knobler; R Martin
Journal:  Ann Intern Med       Date:  1972-10       Impact factor: 25.391

3.  Real-time PCR assay using molecular beacon for quantitation of hepatitis B virus DNA.

Authors:  Simon Siu-Man Sum; Danny Ka-Ho Wong; Man-Fung Yuen; He-Jun Yuan; Jian Yu; Ching-Lung Lai; David Ho; Linqi Zhang
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

4.  Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen.

Authors:  J H Hoofnagle; L B Seeff; Z B Bales; H J Zimmerman
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

Review 5.  Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature.

Authors:  Herve Mommeja-Marin; Elsa Mondou; M Robert Blum; Franck Rousseau
Journal:  Hepatology       Date:  2003-06       Impact factor: 17.425

6.  Treating hepatitis C in methadone maintenance patients: an interim analysis.

Authors:  Diana L Sylvestre
Journal:  Drug Alcohol Depend       Date:  2002-07-01       Impact factor: 4.492

7.  High prevalence of occult hepatitis B in Baltimore injection drug users.

Authors:  Michael Torbenson; Rajesh Kannangai; Jacquie Astemborski; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

8.  Hepatitis B serologic studies in narcotic users with chronic liver disease.

Authors:  D M Novick; A M Gelb; R J Stenger; S R Yancovitz; B Adelsberg; F Chateau; M J Kreek
Journal:  Am J Gastroenterol       Date:  1981-02       Impact factor: 10.864

9.  High seroprevalence of bloodborne viruses among street-recruited injection drug users from Buenos Aires, Argentina.

Authors:  Mercedes Weissenbacher; Diana Rossi; Graciela Radulich; Sergio Sosa-Estáni; Marcelo Vila; Enrique Vivas; María M Avila; Paloma Cuchi; Jorge Rey; Liliana Martínez Peralta
Journal:  Clin Infect Dis       Date:  2003-12-15       Impact factor: 9.079

10.  Chronic hepatitis associated with drug abuse: significance of hepatitis B virus.

Authors:  D J Miller; H Kleber; J R Bloomer
Journal:  Yale J Biol Med       Date:  1979 Jan-Feb
View more
  9 in total

1.  Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions.

Authors:  David C Perlman; Ashly E Jordan; Courtney McKnight; Christopher Young; Kevin L Delucchi; James L Sorensen; Don C Des Jarlais; Carmen L Masson
Journal:  J Addict Dis       Date:  2014

2.  Treating chronic hepatitis C in recovering opiate addicts: yes, we can.

Authors:  M J Kreek; A H Talal; P Piccolo
Journal:  Dig Liver Dis       Date:  2009-02-23       Impact factor: 4.088

Review 3.  Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.

Authors:  David M Novick; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04-16       Impact factor: 6.526

Review 4.  Bidirectional translational research: Progress in understanding addictive diseases.

Authors:  M J Kreek; S D Schlussman; B Reed; Y Zhang; D A Nielsen; O Levran; Y Zhou; E R Butelman
Journal:  Neuropharmacology       Date:  2008-08-07       Impact factor: 5.250

5.  Predictors of hepatitis knowledge improvement among methadone maintained clients enrolled in a hepatitis intervention program.

Authors:  Adeline Nyamathi; Darlene Tyler; Karabi Sinha; Mary Marfisee; Allan Cohen; Barbara Greengold
Journal:  J Community Health       Date:  2010-08

6.  Hepatitis A Virus among Drug Users and the Role of Vaccination: A Review.

Authors:  Fabio Lugoboni; Benedetta Pajusco; Anna Albiero; Gianluca Quaglio
Journal:  Front Psychiatry       Date:  2012-01-12       Impact factor: 4.157

7.  Let It "B"? The role of Hepatitis B universal vaccination among italian problematic drug users.

Authors:  Fabio Lugoboni; Raimondo Maria Pavarin; Chiara Resentera; Daniele Gambini
Journal:  Int J Environ Res Public Health       Date:  2015-04-13       Impact factor: 3.390

Review 8.  Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis.

Authors:  Robert W Aldridge; Alistair Story; Stephen W Hwang; Merete Nordentoft; Serena A Luchenski; Greg Hartwell; Emily J Tweed; Dan Lewer; Srinivasa Vittal Katikireddi; Andrew C Hayward
Journal:  Lancet       Date:  2017-11-12       Impact factor: 79.321

9.  Characterization of occult hepatitis B in high-risk populations in Kenya.

Authors:  Kiptoon Beatrice Jepkemei; Missiani Ochwoto; Ken Swidinsky; Jacqueline Day; Henok Gebrebrhan; Lyle R McKinnon; Anton Andonov; Julius Oyugi; Joshua Kimani; George Gachara; Elijah Maritim Songok; Carla Osiowy
Journal:  PLoS One       Date:  2020-05-28       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.